Bussiness Ideas
Cellara Lifesciences is pioneering OncoSense, an innovative rapid breast cancer detection solution designed to transform early diagnosis and save lives. Breast cancer remains one of the leading causes of death among women worldwide, with millions of new cases each year. The biggest challenge is that many women, especially in rural and underserved communities, are diagnosed at advanced stages due to limited access to mammography, MRI, or genetic testing. These existing methods are either expensive, invasive, or dependent on operator skill, leaving a critical gap in accessible early detection.
OncoSense addresses this need by combining two complementary biomarkers—SCGB2A2, which is breast-specific and highly sensitive for early detection, and CA15-3, which monitors tumor activity across stages 2 to 4—within a gold-nanoparticle-based lateral-flow architecture. This dual-biomarker approach, enhanced by AI-driven analysis, ensures accuracy, reliability, and clinical relevance. The test delivers results in just 15 minutes, is non-invasive, cost-effective, and portable, making it suitable for deployment in outpatient clinics, diagnostic labs, point-of-care settings, and large-scale screening programs.
By bridging the gap between advanced diagnostics and accessibility, OncoSense empowers healthcare providers with timely insights and patients with peace of mind. Its affordability and scalability position it as a breakthrough solution capable of reducing mortality, lowering treatment costs, and democratizing cancer screening for millions of women worldwide.
Show More
